TG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%

TG Therapeutics, Inc. (NASDAQ:TGTX) shares shot up 4.8% on Thursday . The company traded as high as $14.63 and last traded at $14.48. 1,638,056 shares traded hands during trading, a decline of 61% from the average session volume of 4,168,954 shares. The stock had previously closed at $13.82.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TGTX. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. B. Riley boosted their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

TG Therapeutics Stock Up 1.2 %

The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 712.86 and a beta of 2.30. The firm’s fifty day simple moving average is $15.14 and its two-hundred day simple moving average is $13.87.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. The business had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same period in the previous year, the firm earned ($0.39) EPS. Sell-side analysts anticipate that TG Therapeutics, Inc. will post -0.12 EPS for the current year.

Insider Activity

In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now directly owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the business. Pingora Partners LLC purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $27,000. PNC Financial Services Group Inc. increased its stake in TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,014 shares during the period. Macquarie Group Ltd. increased its stake in TG Therapeutics by 102.3% during the 2nd quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 5,152 shares during the period. Coppell Advisory Solutions LLC purchased a new stake in TG Therapeutics during the 2nd quarter worth approximately $46,000. Finally, KBC Group NV purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $54,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.